Rotigotine

Pronunciation: roh-TIG-oh-teen.

Generic name
rotigotine
Drug class
Non-ergolinic dopamine receptor agonist
Form
Once-daily transdermal patch (1, 2, 3, 4, 6, and 8 mg/24 hours, availability varies by market)
Route
Transdermal (skin patch)
Legal status
Prescription-only medicine in every market confirmed this session (United States, United Kingdom, European Union, Canada, Australia, New Zealand); always check your own country and product label.

Availability and supply rules vary by country

Trade names by country: United States · United Kingdom · Canada · Australia · New Zealand

Australia: Neupro (5) · Full directory

What rotigotine is and how it works

Rotigotine is a non-ergolinic dopamine receptor agonist delivered continuously through a once-daily skin patch. It stimulates dopamine receptors in the brain, mimicking the action of dopamine, which is reduced in Parkinson's disease and thought to be involved in restless legs syndrome. (1) (7)

Rotigotine belongs to the same drug class as ropinirole and pramipexole and shares their class-wide safety concerns, including sudden sleep onset and impulse control disorders. A real, now-resolved history is worth knowing honestly: the original US Neupro patch was recalled from the market in April 2008 because the drug could crystallize within the patch and reduce the delivered dose; the product was off the US market for about four years, was reformulated, and returned to the US market in 2012 with broader approved uses. Current labelling reflects the reformulated product, with no ongoing crystallization concern reported.

Mechanism of action: how rotigotine works

Rotigotine is a non-ergolinic dopamine receptor agonist with high in vitro affinity across dopamine receptor subtypes, particularly D3, delivered via continuous transdermal absorption to provide stable 24-hour plasma concentrations. (1)

What rotigotine is used for

Parkinson's disease

Used to treat the signs and symptoms of early-stage Parkinson's disease (alone or combined with levodopa) and advanced-stage Parkinson's disease (combined with levodopa). (1) (2) (3)

Restless legs syndrome (RLS)

Used to treat moderate-to-severe primary restless legs syndrome in adults. (1) (2) (3)

Before taking rotigotine

Do not take / not appropriate for

  • Do not use if you are allergic to rotigotine or any component of the transdermal patch. (all countries) (1) (2)

Tell your clinician about

  • Any history of impulse control problems (gambling, compulsive spending, hypersexuality, binge eating), psychiatric illness, hallucinations, or psychosis.
  • Any history of low blood pressure, fainting, or heart/blood vessel disease.
  • If you are pregnant, planning pregnancy, or breastfeeding.
  • If you have a sulfite allergy (the US formulation contains sodium metabisulfite).
  • If you need an MRI scan or cardioversion -- the patch's backing layer contains aluminium and must be removed beforehand to avoid skin burns.
  • Any other medicines you take, including other Parkinson's or antipsychotic medicines.
(1) (2)

How to take rotigotine

  • Apply one patch once daily, at approximately the same time each day, to clean, dry, intact skin on the abdomen, thigh, hip, flank, shoulder, or upper arm.
  • Rotate the application site daily and do not reapply to the same site within 14 days.
  • Press the patch firmly in place for about 20-30 seconds and do not cut it.
  • Remove the old patch before applying a new one; do not apply heat (heating pads, saunas, direct sunlight) to the patch.
  • Remove the patch before an MRI scan or cardioversion because of the aluminium backing layer.
  • Never stop rotigotine abruptly without talking to your prescriber.
(1) (2)

Procedures and treatment changes

Tell the treating team before surgery, procedures, or any medicine change. Do not alter treatment without the responsible clinician. (1) (2) (3) (4) (5) (6) (7)

Missed dose

If a patch falls off or is missed, apply a new patch for the rest of that day's wear period, then continue with the next patch at the usual scheduled time. Do not apply more than one patch to make up for a missed dose without checking with your prescriber or pharmacist.

Overdose

Remove all patches immediately and seek urgent medical attention if an overdose is suspected. Symptoms can include nausea, vomiting, hypotension, involuntary movements, hallucinations, confusion, and other dopaminergic effects. (1)

Side effects

Side effects and their urgency vary; report severe, persistent, or concerning symptoms.

Application-site reactions (redness, itching, irritation) -- reported at up to 43% incidence at the highest doses studied in US trials.

What to notice: Application-site reactions (redness, itching, irritation) -- reported at up to 43% incidence at the highest doses studied in US trials.

What to do: Discuss persistent or troublesome symptoms with the treating clinician or pharmacist. (1) (3)

Nausea and vomiting.

What to notice: Nausea and vomiting.

What to do: Discuss persistent or troublesome symptoms with the treating clinician or pharmacist. (1) (3)

Somnolence (sleepiness) and dizziness.

What to notice: Somnolence (sleepiness) and dizziness.

What to do: Discuss persistent or troublesome symptoms with the treating clinician or pharmacist. (1) (3)

Headache and sleep disturbances.

What to notice: Headache and sleep disturbances.

What to do: Discuss persistent or troublesome symptoms with the treating clinician or pharmacist. (1) (3)

Loss of appetite (anorexia).

What to notice: Loss of appetite (anorexia).

What to do: Discuss persistent or troublesome symptoms with the treating clinician or pharmacist. (1)

Serious warnings

Sudden onset of sleep or excessive daytime sleepiness — high caution

Symptoms: Falling asleep suddenly during daily activities, including driving, sometimes without any warning signs beforehand, even if you don't otherwise feel drowsy.

Action: Do not drive or operate machinery if this has ever happened to you. Tell your prescriber promptly -- your dose may need to be reduced or the medicine stopped. This can occur at any point during treatment. (1) (2)

Impulse control or compulsive behaviours — high caution

Symptoms: New or increased urges to gamble, unusual sexual urges or hypersexuality, uncontrolled spending or buying, or binge/compulsive eating that feel hard to resist.

Action: Tell your prescriber promptly if you or people close to you notice this. Dose reduction or supervised tapering may be needed. (1) (2)

Application-site skin reactions — moderate caution

Symptoms: Redness, itching, swelling, or irritation where the patch is applied.

Action: Rotate application sites daily and avoid the same site within 14 days. Tell your prescriber if a reaction is severe, spreads, or does not settle after removing the patch. (1) (2)

Hallucinations or abnormal thinking/behaviour — high caution

Symptoms: Seeing or hearing things that are not there, paranoid ideation, delusions, confusion, or psychotic-like behaviour.

Action: Tell your prescriber -- this may require a dose adjustment. Use particular caution if you have a history of major psychiatric or psychotic illness. (1) (2)

Fainting or symptoms of low blood pressure (orthostatic hypotension) — moderate caution

Symptoms: Dizziness or light-headedness on standing, or fainting, particularly when starting treatment or increasing the dose.

Action: Sit or lie down if you feel faint. Tell your prescriber, especially if you have heart or blood vessel disease. Blood pressure monitoring is recommended, particularly at treatment initiation. (1) (2)

MRI scan or cardioversion -- patch must be removed beforehand — important safety information

Symptoms: Not applicable -- this is a device/physical hazard, not a body symptom.

Action: Remove the patch before any MRI scan or cardioversion. The patch's backing layer contains aluminium, which carries a real risk of skin burns if left in place during these procedures. (2) (3)

Worsening restless legs symptoms (augmentation) -- for people using it for RLS — moderate caution

Symptoms: Symptoms starting earlier in the day, becoming more intense, or spreading to other body parts.

Action: Tell your prescriber if this happens -- this is a known dopaminergic-class effect that may require a treatment change. (2)

Sulfite allergy — high caution

Symptoms: Allergic-type reactions, including life-threatening or less severe asthmatic episodes, in sulfite-sensitive people.

Action: Tell your prescriber if you have a known sulfite allergy before starting; the US formulation contains sodium metabisulfite. (1)

Interactions

  • Combining with levodopa may potentiate dopaminergic side effects, including dyskinesia. (1)
  • This dossier's sources did not detail other specific drug-drug interactions in depth. Tell your prescriber about all other medicines you take, including other Parkinson's or antipsychotic medicines, or anything sedating, so they can check for interactions.

Pregnancy, breastfeeding, kidney/liver function, age

Pregnancy

Based on animal data, rotigotine may cause fetal harm (US label); the UK/EU SmPC states rotigotine is contraindicated in pregnancy. Discuss with your prescriber before use if pregnant or planning pregnancy. (1) (2) (3) (4) (5) (6) (7)

Breastfeeding

UK/EU labelling advises breastfeeding should be discontinued during treatment because rotigotine suppresses prolactin secretion and is excreted in milk. (1) (2) (3) (4) (5) (6) (7)

Children

Not established as safe and effective in children; not indicated for paediatric use in the sources reviewed for this dossier. (1) (2) (3) (4) (5) (6) (7)

Elderly

No specific dose adjustment based on age alone is described in the sources reviewed, beyond the standard individualised titration used for all adults. (1) (2) (3) (4) (5) (6) (7)

Hepatic_impairment

Use with caution; specific dose-adjustment data are limited in the sources reviewed for this dossier -- consult your prescriber. (1) (2) (3) (4) (5) (6) (7)

Renal_impairment

This dossier's sources did not detail specific renal dosing guidance -- consult your prescriber if you have kidney problems. (1) (2) (3) (4) (5) (6) (7)

Monitoring

Before starting

  • Baseline blood pressure.
  • Screen for history of impulse control problems, psychiatric illness, or hallucinations.
  • Confirm no known sulfite allergy (US formulation).

During treatment

  • Regular monitoring for impulse control or compulsive behaviours, ideally involving family/caregivers.
  • Monitor for sudden sleepiness, dizziness, or fainting, especially at treatment initiation or dose changes.
  • Check application sites regularly for skin reactions.
(1) (2)

Storage

Store at room temperature. Keep the patch in its individual pouch until ready to use. Fold used patches in half with the sticky sides together and dispose of safely, out of reach of children and pets (used patches still contain active medicine).

Study the drug class: Antiparkinsonian agents

Professional information

Clinician-facing context only, sourced from the current US DailyMed prescribing information plus UK EMC, EU EMA, Health Canada, Australia TGA, and New Zealand classification/funding sources reviewed for this dossier; verify against the current full label for the specific product before prescribing.

United States, United Kingdom, European Union, Canada, Australia

Indication: Parkinson's disease and restless legs syndrome

Dose summary: Individualised titration starting from a low dose (commonly 1-2 mg/24h), increased gradually according to response and tolerability up to indication-specific maximum doses; RLS maximum dose is lower than the Parkinson's disease maximum.

Renal context: Sources reviewed for this dossier did not detail specific renal dosing guidance. (1) (2)

Mechanism of action

Hepatic guidance

Use with caution in hepatic impairment; specific dose-adjustment data are limited per the sources reviewed.

Overdose note

Manage supportively; remove all patches immediately. No specific antidote; monitor for dopaminergic toxicity (hypotension, dyskinesia, hallucinations). (1)

Frequently asked questions

Is rotigotine (Neupro) available in the US, UK, EU, Canada, Australia, and New Zealand?

Yes, confirmed via direct regulator sources: the United States (DailyMed, reformulated version marketed since 2012), United Kingdom (EMC-licensed SmPC), European Union (EMA centralised authorisation since 2006), Canada (Health Canada Drug Product Database, marketed status), and Australia (TGA ARTG registration since 2007). New Zealand is confirmed as a prescription-classified medicine via a 2008 Medicines Classification Committee minute and a 2023 Pharmac funding-application record, though a live current Medsafe data sheet could not be independently re-fetched this session. (1) (2) (3) (4) (5) (6)

Was Neupro ever taken off the market?

Yes. The original US Neupro patch was recalled/withdrawn from the market in April 2008 because the drug could crystallize within the patch, potentially reducing the delivered dose. It was off the US market for about four years, was reformulated, and returned to the US market in 2012 with broader approved indications. This is real, resolved history -- current labelling reflects the reformulated product with no ongoing crystallization concern reported. (7) (1)

What is the most important safety warning for rotigotine?

Two class-wide dopamine-agonist warnings stand out: sudden onset of sleep during daily activities (including driving), sometimes without any warning signs, and impulse control disorders such as compulsive gambling, spending, hypersexuality, or binge eating. Both require prompt reporting to your prescriber. (1) (2)

Can I have an MRI scan while using a Neupro patch?

Remove the patch before an MRI scan or cardioversion. The patch's backing layer contains aluminium, which carries a real risk of skin burns if left in place during these procedures. (2) (3)

What is the mechanism of action of rotigotine?

Rotigotine is a non-ergolinic dopamine receptor agonist with high in vitro affinity across dopamine receptor subtypes, particularly D3, delivered via continuous transdermal absorption to provide stable 24-hour plasma concentrations. (1)

What is the generic name of Rotigotine?

The generic name is rotigotine. (1) (5)

What class of drug is rotigotine?

Rotigotine is classed as: Non-ergolinic dopamine receptor agonist. (1) (5)

References

  1. NEUPRO (rotigotine) transdermal system extended release -- full prescribing informationDailyMed (U.S. National Library of Medicine) -- FDA-approved prescribing information · United States · accessed 2026-07-30 · source 1
  2. Neupro 2 mg/24 h Transdermal Patch -- SmPCelectronic medicines compendium (emc), United Kingdom -- Summary of Product Characteristics · United Kingdom · accessed 2026-07-30 · source 2
  3. Neupro (rotigotine) -- EPAR overviewEuropean Medicines Agency (EMA) -- European Public Assessment Report (EPAR) · European Union · accessed 2026-07-30 · source 3
  4. NEUPRO (rotigotine) transdermal system -- Drug Product Database listingHealth Canada -- Drug Product Database (DPD) · Canada · accessed 2026-07-30 · source 4
  5. NEUPRO rotigotine transdermal patch sachet -- ARTG entries (131383, 131370, 163987)Therapeutic Goods Administration (TGA), Australia -- ARTG entries · Australia · accessed 2026-07-30 · source 5
  6. Rotigotine classification (2008) and Neupro funding-application review (2023)Medsafe Medicines Classification Committee (2008 minute) and Pharmac Neurological Advisory Committee (2023 record) -- New Zealand government sources · New Zealand · accessed 2026-07-30 · source 6
  7. Rotigotine (Neupro) patch recall due to drug crystallization (2008) and reformulated US relaunch (2012)Multiple secondary clinical/pharmacy news sources reporting on the real 2008 FDA-related recall and 2012 reformulated reintroduction · United States · accessed 2026-07-30 · source 7

Brand names by country

Single-ingredient rotigotine names are shown separately by country. Product availability, strengths, and supply rules can change; combination products are not included here.

Priority countries

United States

  • Neupro8 mg/24h, 6 mg/24h, 1 mg/24h, 3 mg/24h, 4 mg/24h, 2 mg/24h · ucb, inc.

United Kingdom

  • Neupro (2)MHRA licensed confirmed · 1 mg/24h, 2 mg/24h, 3 mg/24h, 4 mg/24h, 6 mg/24h, 8 mg/24h · UCB Pharma Ltd

Canada

  • NEUPRO

Australia

  • Neupro (5)TGA ARTG registered 2007-11-22 confirmed · 1 mg/24h, 2 mg/24h, 4 mg/24h, 6 mg/24h, 8 mg/24h · UCB Australia Pty Ltd

New Zealand

  • Neupro (6)Medsafe prescription classified 2008 Pharmac funding review 2023 · not independently re-confirmed this session · not independently re-confirmed this session
View brands in additional countries.

European Union

Neupro (3)

This page provides general reference information about rotigotine (Neupro) and is not a substitute for advice from your pharmacist or clinician. Never start, stop, or change your dose without medical supervision, especially given the risk of sudden sleepiness and impulse control changes.

Related medicines